- $244.83m
- $44.80m
- 51
- 37
- 85
- 59
Annual cashflow statement for XBiotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 669 | -11.2 | -17.4 | -32.9 | -24.6 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -747 | 10.4 | 6.64 | 7.86 | 1.37 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 57.8 | -66.5 | 77 | 7.6 | 2.78 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -18.3 | -65.1 | 69.4 | -14.8 | -18.7 |
| Capital Expenditures | -0.204 | -3.73 | -3.52 | -0.585 | -0.362 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 675 | 0 | 0 | -63.3 | 61.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 675 | -3.73 | -3.52 | -63.9 | 61.5 |
| Financing Cash Flow Items | 0.302 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 42.1 | -410 | -67 | 0 | -0.009 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 699 | -477 | -0.383 | -79.7 | 42.7 |